TY - JOUR
T1 - Molecular alterations in Barrett's esophagus and adenocarcinoma
AU - Ozawa, S.
AU - Ando, N.
AU - Kitagawa, Y.
AU - Ueda, M.
AU - Kitajima, M.
PY - 1999/3
Y1 - 1999/3
N2 - Patients with Barrett's columnar-lined esophagus are at increased risk of developing esophageal adenocarcinoma, the incidence of which has increased rapidly especially in the USA. Although the number of patients with Barrett's adenocarcinoma is fewer in Japan than in the USA, all gastroenterologist should know its multistep carcinogenic process. Tumor suppressor genes (p53, p16), oncogenes (c-erbB-2, H-ras, K-ras, cyclin D1, src), and growth factor/receptor (TGF-alpha, EGFR) seem to cause the malignant transformation of Barrett's esophagus. Because detection of these molecular alterations is feasible, more accurate diagnosis of Barrett's esophageal biopsy specimens should be made by adding the molecular examination to the conventional pathologic examination.
AB - Patients with Barrett's columnar-lined esophagus are at increased risk of developing esophageal adenocarcinoma, the incidence of which has increased rapidly especially in the USA. Although the number of patients with Barrett's adenocarcinoma is fewer in Japan than in the USA, all gastroenterologist should know its multistep carcinogenic process. Tumor suppressor genes (p53, p16), oncogenes (c-erbB-2, H-ras, K-ras, cyclin D1, src), and growth factor/receptor (TGF-alpha, EGFR) seem to cause the malignant transformation of Barrett's esophagus. Because detection of these molecular alterations is feasible, more accurate diagnosis of Barrett's esophageal biopsy specimens should be made by adding the molecular examination to the conventional pathologic examination.
UR - http://www.scopus.com/inward/record.url?scp=0033094824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033094824&partnerID=8YFLogxK
M3 - Review article
C2 - 10379532
AN - SCOPUS:0033094824
SN - 0301-4894
VL - 100
SP - 235
EP - 239
JO - Nihon Geka Gakkai zasshi
JF - Nihon Geka Gakkai zasshi
IS - 3
ER -